Effect and safety analysis of clopidogrel combined with ezetimibe in the treatment of angina pectoris of coronary heart disease
Objective To analyze the effect and safety of clopidogrel combined with ezetimibe in the treatment of angina pectoris of coronary heart disease.Methods A total of 80 patients with angina pectoris of coronary heart disease were randomly divided into a study group(40 cases)and a control group(40 cases).The control group was treated with ezetimibe alone,and the study group was treated with ezetimibe combined with clopidogrel.The clinical indicators,total cholesterol(TC),triglyceride(TG),endothelin-1(ET-1),nitric oxide(NO),and drug safety of the two groups were compared.Results After treatment,the duration of angina pectoris of(8.89±0.71)min/time in the study group was shorter than(9.32±0.86)min/time in the control group,and the frequency of angina pectoris of(2.03±0.15)times/week was lower than(4.59±0.29)times/week in the control group.The difference was statistically significant(P<0.05).After treatment,TG and TC in the study group were(1.18±0.16)and(3.16±0.82)mmol/L,which were lower than(1.59±0.23)and(4.72±1.01)mmol/L in the control group,and the difference was statistically significant(P<0.05).After treatment,ET-1 of(67.45±5.23)ng/L in the study group was lower than(74.16±4.12)ng/L in the control group,and NO of(82.57±5.18)μmol/L was higher than(71.73±4.15)μmol/L in the control group.The difference was statistically significant(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the study group(7.50% )and the control group(10.00% )(P>0.05).Conclusion In the clinical treatment of angina pectoris of coronary heart disease,the combined application of ezetimibe and clopidogrel has a more obvious effect,which can improve the blood lipid level and indicators of ET-1 and NO.Moreover,the combination of drugs in patients does not cause serious adverse reactions,which has a high safety.
ClopidogrelEzetimibeAngina pectoris of coronary heart diseaseClinical efficacySafety